UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 2, 2011
Bacterin International Holdings, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
|
(State or Other Jurisdiction of Incorporation)
|
|
|
001-34951
|
20-5313323
|
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
600 Cruiser Lane
Belgrade, Montana
|
59714
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(406) 388-0480
|
|
(Registrant’s Telephone Number, Including Area Code)
|
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
The Company has released scheduling information regarding its conference call to discuss first quarter 2011 financial results, and a copy of a press release entitled “Bacterin International Holdings, Inc. Schedules Conference Call to Present First Quarter 2011 Financial Results” is attached as Exhibit 99.1 and incorporated herein.
The information in this Item 7.01 and the documents attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No
|
Description
|
|
|
|
||
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated May 2, 2011 entitled “Bacterin International Holdings, Inc. Schedules Conference Call to Present First Quarter 2011 Financial Results”
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BACTERIN INTERNATIONAL HOLDINGS, INC. | |||
|
Dated: May 2, 2011
|
By:
|
/s/ Guy S. Cook | |
|
Name: Guy S. Cook
|
|||
|
Title: President and Chief Executive Officer
|
|||
EXHIBIT INDEX
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated May 2, 2011 entitled “Bacterin International Holdings, Inc. Schedules Conference Call to Present First Quarter 2011 Financial Results”
|
|||
Bacterin International Holdings, Inc. Schedules Conference Call to Present First Quarter 2011 Financial Results
BELGRADE, MT, – May 2, 2011 – Bacterin International Holdings, Inc. (NYSE Amex: BONE) (“Bacterin”), announced today that it has scheduled a conference call for Thursday, May 12, 2011 at 4:30 p.m. (ET) to discuss the Company’s financial results for its first quarter 2011, which ended March 31, 2011. Bacterin International Holdings, Inc. intends to issue its earnings release after the market close on the day of the conference call.
Conference Call Details:
|
Date/Time:
|
Thursday, May 12, 2011—4:30 p.m. (ET)
|
|
Telephone Number:
|
888-713-4216
|
|
International Dial-In Number:
|
617-213-4868
|
|
Participant Pass code:
|
87304304
|
|
Internet Access:
|
www.bacterin.com or www.earnings.com
|
It is recommended that participants phone-in at least 10 minutes before the call is scheduled to begin. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PM83BKEBN
Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection. A replay of the conference call in its entirety will be available approximately one hour after its completion by dialing 888-286-8010 (U.S.), 617-801-6888 (International) and entering the pass code 46840748 and on the Internet at www.earnings.com.
Investor Contact:
Yvonne L. Zappulla
Managing Director
Grannus Financial Advisors, Inc.
212-681-4108
Yvonne@GrannusFinancial.com
About Bacterin International Holdings, Inc.
BACTERIN INTERNATIONAL HOLDINGS, INC. ("the "Company" or "Bacterin") develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot., state-of-the-art, fully compliant and FDA registered facility, equipped with five "Class 100" clean rooms. For further information please visit www.bacterin.com.
Certain statements in this news release may constitute “forward-looking” statements within the meaning of section 21E of the Securities and Exchange Act of 1934. The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations. These statements are not, however, guarantees of future performance and actual results may differ materially. Risk factors are listed in the Company’s most recent Form 10-K filed with the Securities and Exchange Commission.